CRISPR Therapeutics AG stock page - price, fundamentals, dividends - iOCharts

Ticker
CRSP

Price
52.23
Stock movement up
+5.69 (12.23%)
Company name
CRISPR Therapeutics AG
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
4.04B
Ent value
3.72B
Price/Sales
4.42
Price/Book
1.80
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
12.97
Forward P/E
-
PEG
-
EPS growth
54.00%
1 year return
-51.02%
3 year return
10.54%
5 year return
25.17%
10 year return
-
Last updated: 2022-05-13

DIVIDENDS

CRSP does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E12.97
Price to OCF8.02
Price to FCF9.76
Price to EBITDA11.97
EV to EBITDA11.01

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.42
Price to Book1.80
EV to Sales4.06

FINANCIALS

Per share

Loading...
Per share data
Current share count77.40M
EPS (TTM)4.07
FCF per share (TTM)5.41

Income statement

Loading...
Income statement data
Revenue (TTM)915.36M
Gross profit (TTM)914.42M
Operating income (TTM)312.10M
Net income (TTM)311.61M
EPS (TTM)4.07
EPS (1y forward)-6.83

Margins

Loading...
Margins data
Gross margin (TTM)99.90%
Operating margin (TTM)34.10%
Profit margin (TTM)34.04%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash683.91M
Net receivables143.00K
Total current assets2.26B
Goodwill0.00
Intangible assets112.00K
Property, plant and equipment0.00
Total assets2.61B
Accounts payable27.11M
Short/Current long term debt238.98M
Total current liabilities113.70M
Total liabilities361.26M
Shareholder's equity2.24B
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)504.40M
Capital expenditures (TTM)90.03M
Free cash flow (TTM)414.37M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity13.88%
Return on Assets11.96%
Return on Invested Capital13.81%
Cash Return on Invested Capital18.37%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open48.19
Daily high52.80
Daily low48.19
Daily Volume1.56M
All-time high210.04
1y analyst estimate132.18
Beta2.01
EPS (TTM)4.07
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
CRSPS&P500
Current price drop from All-time high-75.13%-15.91%
Highest price drop-79.42%-56.47%
Date of highest drop9 May 20229 Mar 2009
Avg drop from high-31.16%-11.33%
Avg time to new high23 days12 days
Max time to new high520 days1805 days
COMPANY DETAILS
CRSP (CRISPR Therapeutics AG) company logo
Marketcap
4.04B
Marketcap category
Mid-cap
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Employees
473
Investor relations
SEC filings
CEO
Samarth Kulkarni
Country
USA
City
Zug
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Shares of Editas Medicine (NASDAQ: EDIT), a genome editing biotech company that uses CRISPR/Cas9 and CRISPR/Cas12a genome editing systems to develop therapies, saw its shares plummet 28.9% this week, ...
May 13, 2022
Let's look at two stocks that boast significant upside potential, going by average price targets set by analysts on the street: Moderna (NASDAQ: MRNA) and CRISPR Therapeutics (NASDAQ: CRSP). Biotech ...
May 13, 2022
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.
May 12, 2022
ZUG, Switzerland and CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...
May 12, 2022
CRISPR Therapeutics (CRSP) reports wider-than-expected Q1 loss. Revenues miss estimates.
May 10, 2022
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -21.47% and 83.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock...
May 9, 2022
- More than 75 patients dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; planned global regulatory submissions on track for late 2022- -Initiated two new CTX001 Phase 3 clinical tri...
May 9, 2022
If you want to know who really controls CRISPR Therapeutics AG ( NASDAQ:CRSP ), then you'll have to look at the makeup...
May 9, 2022
Vertex Pharmaceuticals' (VRTX) earnings miss estimates while sales beat the same for the first quarter of 2022. The company maintains its revenue guidance for 2022.
May 6, 2022
ZUG, Switzerland and CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...
May 4, 2022
Next page